本帖最后由 老马 于 2013-3-13 13:43 编辑 @/ Z9 p! e8 t# ^# E% U
- G: k' B& V8 X" K9 ^, W9 ?
健择(吉西他滨)+顺铂+阿瓦斯汀
u, @0 m7 [6 N' ]* L. O( I8 q Gemzar +Cisplatin + Avastin
, }0 s4 y- p! u. g8 _+ g- K! p' Qhttp://annonc.oxfordjournals.org/content/21/9/1804.full( E" } i4 V9 H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : O I8 a: V! B' {
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 ]! H1 i' X# L( v* _Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; K6 g7 d4 a {" j- f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 806)
- u' F0 ^* w- D5 \. m3 E, S华为网盘附件:* W4 s: E4 J W9 b6 ?" |9 G
【华为网盘】ava.JPG' b) Q* F d% N8 {2 B! `
|